Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck KGaA states no new Raptiva prescriptions

Merck KGaA states no new Raptiva prescriptions

20th February 2009

Merck KGaA has asserted physicians in the European Union should not issue any new prescriptions for Raptiva (eflizumab).

This comes after a recommendation from the European Medicines Agency to the European Commission that the marketing authorisation of the drug should be suspended.

There have been three virologically confirmed cases of progressive multifocal leukoencephalopathy in people with psoriases who were treated with Raptiva over the past five months ? one of whom was a 47-year-old patient from Germany.

As well as no longer prescribing the medication, doctors are advised to assess the most suitable alternatives for those who are currently receiving the drug and they should be monitored for neurological symptoms and infection.

It is important for those taking the treatment to go and see a medical professional to discuss other options and to also not stop using it abruptly.

Sales of Raptiva in 2008 totalled 93 million euros (82.36 million pounds), having a negative impact on Merck KGaA’s profits.

Last year it wrote off the rights for the medication.

Established in 1668, the firm currently employs around 32,800 staff in 59 countries.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.